The ATCC has now developed an EML4-ALK fusion NSCLC cell line (ATCC® CCL-185IGTM; www.atcc.org) that can be used to validate the detection of this rearrangement in patients with cancer to aid in forming a precise treatment plan. The gene discussed is EML4; the disease is cancer.